GlassScriptPhysician profile
Taisha W Gonzalez
NPI 1023638483
$500.62
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $345.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.36 | 2021-2022 | |
| Lilly USA, LLC | $62.67 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $52.85 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.04 | 2022 | |
| Pfizer INC. | $37.57 | 2022 | |
| Endogastric Solutions, INC | $28.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.73 | 2022 | |
| Eisai INC. | $23.96 | 2021 | |
| Philips North America LLC | $21.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.88 | 2022 | |
| Boston Scientific Corporation | $16.65 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.11 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.89 | 2021 | |
| Fidia Pharma USA INC. | $13.34 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.48 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taisha Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.